Editas Medicine Inc. | TalkMarkets

Latest Posts

Bull Of The Day: Crispr Therapeutics

Article By: Zacks Investment Research

Monday, December 11, 2023 6:43 AM EDT

CRISPR Therapeutics (CRSP) just made history on Friday with the first FDA-approved gene-editing medicine based on the Nobel Prize-winning discovery that targets disease with the billion-year old defense mechanism bacteria use to battle viruses.

In this article: CRSP Also: VRTX, EDIT

Read

Looking For Growth In Small And Mid Cap Life Science Stocks

Article By: Rod Raynovich

Monday, November 15, 2021 4:00 PM EDT

2021 is an unusual year for biotech with a “blow-off” February high in speculative small caps.

In this article: CYRX, QDEL, PACB, XBI, TDOC, EDIT, NTLA, CRSP, MGTX, VCYT

Read

Biotech Playbook Revisited As Technicals Weaken

Article By: Rod Raynovich

Monday, September 27, 2021 12:23 PM EDT

Recent breakthroughs with mRNA vaccines over the past two years have shown the enormous potential for transformative therapies. DNA sequencing took off five years ago and new applications are still being developed.

In this article: CYRX, QDEL, IWF, CRSP, ARKG, VCYT, IBB, XLV, EDIT, PRHSX

Read

A Comprehensive Guide To Genomic ETFs

Article By: Zacks Investment Research

Sunday, July 11, 2021 1:59 PM EDT

Given the growing applications of gene-editing, it is a rising market which offers endless opportunities. Growing demand for personalized medicine, solid investments and higher R&D activities will soon make genomics the next big thing in the space.

In this article: GNOM, PBE, ARKG, IDNA, NTLA, CRSP Also: BEAM, EDIT

Read